Oncotarget

Research Papers:

Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative

Shumin Zhang, Lajos Gera, Kenza Mamouni, Xin Li, Zhengjia Chen, Omer Kucuk and Daqing Wu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2016; 7:27489-27498. https://doi.org/10.18632/oncotarget.8481

Metrics: PDF 1663 views  |   HTML 2151 views  |   ?  


Abstract

Shumin Zhang1,*, Lajos Gera2,*, Kenza Mamouni3, Xin Li3, Zhengjia Chen4, Omer Kucuk5, Daqing Wu1,3,6

1Department of Urology, Emory University School of Medicine, Atlanta, GA, USA

2Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Anschutz Medical Campus, School of Medicine, Aurora, CO, USA

3Department of Biochemistry and Molecular Biology, Medical College of Georgia and GRU Cancer Center, Augusta University, Augusta, GA, USA

4Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA

5Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA

6MetCure Therapeutics LLC, Atlanta, GA, USA

*These authors contributed equally to this work

Correspondence to:

Daqing Wu, email: [email protected]

Keywords: prostate cancer, bone metastasis, survivin inhibitor, docetaxel resistance, preclinical models

Received: January 07, 2016     Accepted: March 18, 2016     Published: March 30, 2016

ABSTRACT

Bone metastasis is a major cause of prostate cancer (PCa) morbidity and mortality. Despite some success in transiently controlling clinical symptoms with docetaxel-based therapy, PCa patients become docetaxel-resistant and inevitably progress with no cure. We synthesized an acyl-tyrosine bisphosphonate amide derivative, BKM1644, with the intent of targeting bone metastatic PCa and enhancing docetaxel’s efficacy. BKM1644 exhibits potent anti-cancer activity in the NCI-60 panel and effectively inhibits the proliferation of metastatic, castration-resistant PCa (mCRPC) cells, with IC50 ranging between 2.1 μM and 6.3 μM. Significantly, BKM1644 sensitizes mCRPC cells to docetaxel treatment. Mice with pre-established C4-2 tumors in the tibia show a marked decrease in serum prostate-specific antigen (control: 173.72 ± 37.52 ng/ml, combined treatment: 64.45 ± 22.19 ng/ml; p < 0.0001) and much improved bone architecture after treatment with the combined regimen. Mechanistic studies found that docetaxel temporarily but significantly increases survivin, an anti-apoptotic protein whose overexpression has been correlated with PCa bone metastasis and therapeutic resistance. Intriguingly, BKM1644 effectively inhibits survivin expression, which may antagonize docetaxel-induced survivin in bone metastatic PCa cells. Signal transducer and activator of transcription 3 (Stat3) may be involved in the suppression of survivin transcription by BKM1644, as confirmed by a survivin reporter assay. Collectively, these data indicate that BKM1644 could be a promising small-molecule agent to improve docetaxel efficacy and retard the bone metastatic growth of PCa.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8481